What is Balt Group?
For over 45 years, Balt has been a pioneering force in developing advanced neurovascular solutions, collaborating closely with physicians and institutions. As a premier global neurovascular platform, Balt is dedicated to pushing innovation beyond existing boundaries and is now extending its expertise into the peripheral vascular space. This expansion signifies a strategic move to leverage its established capabilities in a new, high-growth market segment.
How much funding has Balt Group raised?
Balt Group has raised a total of $370M across 1 funding round:
Other Financing Round
$370M
Other Financing Round (2024): $370M with participation from Bridgepoint Advisers Group
Key Investors in Balt Group
Bridgepoint Advisers Group
Bridgepoint Advisers Group is an international private equity firm with a focus on investing in and developing businesses across various sectors, including healthcare. Their involvement suggests a strategic alignment with Balt Group's long-term growth objectives and market expansion plans.
What's next for Balt Group?
The recent major strategic investment signals a new phase of accelerated growth and market penetration for Balt Group. This capital is expected to fuel further research and development, enhance manufacturing capabilities, and support the expansion of its commercial reach, particularly in the peripheral vascular market. The company's long-standing expertise in neurovascular solutions positions it favorably to replicate its success in this adjacent field, aiming to solidify its leadership across a broader spectrum of vascular interventions.
See full Balt Group company page
